The goal of this training program is to prepare physicians and basic scientists for careers focused on the development and use of radionucleotides in the diagnosis and treatment of cancer. Support is requested for five trainees, who may be either physicians or basic scientists. Physician trainees will have completed the major portion of requirements for board certification in nuclear medicine. Basic science trainees will hold the Ph.D. degree in chemistry, physics, biology, or a related science.. Each will be aiming for a career in research in a academic setting. The training program will be two to three years in duration. A broad based didactic curriculum will cover fully the field of nuclear medicine as applied to cancer. Each trainee will give focused concentration in selected tracks coordinated by a senior faculty mentor. Specific research tracks are: (1) Tumor antibodies/radiopharmaceutical, (2) Endocrine tumors, (3) Brain tumors, (4) Radiopharmaceutical therapy, (5) Quantitative radionuclide imaging, and (6) Radiopharmaceutical development. Research in one or a combination of these tracks will involve at least 50-75% of trainee time. The program will be conducted in the Division of Nuclear Medicine and Comprehensive Cancer Center facilities. Training will be supervised by members of the large, multi- disciplinary nuclear medicine faculty. This group publishes over 90 papers per year and receives over 6 million dollars per year in research grant support. Nuclear Medicine facilities include 90,000 square feet of clinic space, 17,000 square feet of laboratory space, a dedicated cyclotron, and 3 PET scanners. This program is integrated with University of Michigan Comprehensive Cancer Center activities. The combination of faculty motivation, structured curricula, excellent facilities, and superb intellectual environment is expected to prepare individuals to be tomorrow's leaders in cancer research.
Showing the most recent 10 out of 53 publications
